The FDA’s Double Standard: Reviewing Safety While Expanding Abortion Pill Access

The FDA just promised a safety review for the abortion pill mifepristone—but not even two weeks later, they quietly approved a new generic version. What does this mean for women, unborn children, and the integrity of federal oversight?

In this video, Julie Barrett of Conservative Ladies of America breaks down the FDA’s contradictory actions, the new congressional bill to restore safeguards (H.R. 5646), and why we can’t just take these agencies at their word.

📌 Watch the full breakdown and see why “playing both sides” may put lives at risk.
📌 Read our previous coverage on the abortion pill timeline: https://conservativeladiesofamerica.substack.com/p/restoring-safeguards-congress-responds
📌 Stay informed and join the conversation in the comments below.

Support our work - donate today! https://www.givesendgo.com/conservativeladiesus

#FDA #AbortionPill #Mifepristone #HHS #TrumpAdministration #ConservativeLadies